Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from ME Therapeutics Holdings, Inc. ( (TSE:METX) ) is now available.
ME Therapeutics Holdings Inc. has secured a U.S. patent for its lead G-CSF antibody candidate, marking a significant milestone in its drug development efforts. This patent, which protects the therapeutic use of the antibody for cancer treatment, is expected to bolster the company’s position in the immuno-oncology field. Alongside this achievement, ME Therapeutics is advancing its therapeutic mRNA and in vivo CAR programs through preclinical testing, and expanding its research team to accelerate progress towards clinical trials.
More about ME Therapeutics Holdings, Inc.
ME Therapeutics Holdings Inc. is a publicly listed biotechnology company based in Vancouver, specializing in the development of novel immuno-oncology therapeutics. The company’s pipeline focuses on enhancing immune recognition of cancer cells and overcoming immune suppression within the tumor microenvironment.
Average Trading Volume: 761
Technical Sentiment Signal: Strong Sell
See more data about METX stock on TipRanks’ Stock Analysis page.